Evidence map›Paper›PMID 41934550›Full record

ArticleMolecular and cellular biochemistry2026

CREB1-ROC1 axis drives bladder cancer progression under hypoxic conditions.

Zhenchao Sun, Yingyu Wang, Shengjie You, Qingfen Ji, Xiang Liu, Pengfei Bao, Huijiang Zhang, Xiaoqing Zhou, Junjie Ye, Peng Li and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhenchao Sun *Department of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Yingyu Wang *School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, 323000, Zhejiang, China.
Shengjie YouDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Qingfen JiDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Xiang LiuDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Pengfei BaoDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Huijiang ZhangDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Xiaoqing ZhouDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Junjie YeDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
Peng LiDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China. 18957091072@189.com.
Qi WuDepartment of Urology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China. UrologyQi@163.com.

Funding

Lishui Public Welfare Technology Application Research Project 2024GYX29, 2024SJZC119, 2024SJZC115This work was supported by the Zhejiang Medical and Health Science and Technology Program 2025KY1974, 2024KY1864, 2025KY504, 2025KY1975, 2024KY1867, 2024KY587Zhejiang Public Welfare Technology Application Research Project LBY24H180007
6 · The paper itself

Abstract

Hypoxia is a hallmark of tumor microenvironments that promotes bladder cancer (BCa). We aimed to study the upstream transfector of ROC1 on malignant oncological characteristics of BCa cells under hypoxic conditions, and clarified the regulating mechanisms involved. The expressions of ROC1 and HIF1A were mediated by RT-qPCR and western blot. The upstream transcription factor of ROC1 was analyzed by bioinformatic analysis and examined by clinical data. The BCa cell lines (T24 and 5637) were treated CREB1 overexpression or knockdown. The hypoxia induction was conducted, and cell proliferation, apoptosis, migration and invasion were subsequently studied. The rescue experiments in vitro and in vivo were performed to explore the underlying regulating mechanism of CREB1. ROC1 was down-regulated in bladder cancer tissues and hypoxia condition. CREB1 was an upstream transcription factor of ROC1. CREB1 expression was correlated with T Stage in BCa, while ROC1expression was associated with N Stage in BCa patients. CREB1 promoted the proliferation and inhibited the apoptosis of BCa cells under hypoxia. CREB1 regulated the invasion, migration, and expressions of Bcl−2, Bax, cleaved caspased−3, MMP2, and MMP9 in BCa cells under hypoxia. Down-regulation of ROC1 reversed CREB1’s effect on BCa cells. Similarly, HIF1A knockdown also reversed CREB1’s impact on BCa cells. CREB1 promoted tumor growth in vivo and shROC1 reversed its effect. Our study indicated that CREB1-ROC1 axis is a hypoxia-responsive therapeutic target in BCa, which can provide new insights for BCa early screening, prevention and treatment.

Indexed as

Cyclic AMP Response Element-Binding ProteinNeoplasm ProteinsUrinary Bladder NeoplasmsAnimalsApoptosisCell HypoxiaCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMembrane Transport ProteinsMiceCREB1 protein, humanCyclic AMP Response Element-Binding ProteinMembrane Transport ProteinsNeoplasm ProteinsOSCP1 protein, humanBladder cancerCREB1InvasionProliferationROC1

Identifiers

PMID41934550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.